中国医疗前沿
中國醫療前沿
중국의료전연
CHINA HEALTHCARE INNOVATION
2013年
19期
57-58
,共2页
晚期胃癌%替吉奥%奥沙利铂%联合化疗
晚期胃癌%替吉奧%奧沙利鉑%聯閤化療
만기위암%체길오%오사리박%연합화료
Advanced gastric cancer%TS-1 capsule%Oxaliplatin%Combination chemotherapy
目的:观察替吉奥联合奥沙利铂治疗晚期胃癌的疗效和安全性。方法30例患者随机分为两组各15例,实验组给予替吉奥胶囊(80mg/m2)/d,分2次口服,d1-14;奥沙利铂130mg/m2,静脉滴注,d1。对照组给予替加氟800mg/m2静脉滴注, d1-5;亚叶酸钙100mg静脉滴注,d1-5;奥沙利铂130mg/m2,静脉滴注,d1。3周为1个周期,化疗2周期后评价疗效。结果两组总有效率无统计学差异(P >0.05),两组主要的毒副反应均为消化道反应、血液学毒性及外周神经毒性。结论替吉奥胶囊联合奥沙利铂治疗进展期胃癌安全、有效。
目的:觀察替吉奧聯閤奧沙利鉑治療晚期胃癌的療效和安全性。方法30例患者隨機分為兩組各15例,實驗組給予替吉奧膠囊(80mg/m2)/d,分2次口服,d1-14;奧沙利鉑130mg/m2,靜脈滴註,d1。對照組給予替加氟800mg/m2靜脈滴註, d1-5;亞葉痠鈣100mg靜脈滴註,d1-5;奧沙利鉑130mg/m2,靜脈滴註,d1。3週為1箇週期,化療2週期後評價療效。結果兩組總有效率無統計學差異(P >0.05),兩組主要的毒副反應均為消化道反應、血液學毒性及外週神經毒性。結論替吉奧膠囊聯閤奧沙利鉑治療進展期胃癌安全、有效。
목적:관찰체길오연합오사리박치료만기위암적료효화안전성。방법30례환자수궤분위량조각15례,실험조급여체길오효낭(80mg/m2)/d,분2차구복,d1-14;오사리박130mg/m2,정맥적주,d1。대조조급여체가불800mg/m2정맥적주, d1-5;아협산개100mg정맥적주,d1-5;오사리박130mg/m2,정맥적주,d1。3주위1개주기,화료2주기후평개료효。결과량조총유효솔무통계학차이(P >0.05),량조주요적독부반응균위소화도반응、혈액학독성급외주신경독성。결론체길오효낭연합오사리박치료진전기위암안전、유효。
Objective To observe therapeutic effect and safety of gimeracil and oteracil porassium capsules combined with oxaliplatin in the treatment of advanced gastric cancer. Methods All 30 cases were divided into two groups randomly, the trial group(15 cases), TS-1 capsule(80mg/m2)/d, twice a day peroral, d1-14; oxaliplatin 130mg/m2,intravenous drip, d1. The control groups(15 cases), tegafur 800mg/m2, intravenous drip, d1-5; CF 100mg,intravenous drip, d1-5;oxaliplatin 130mg/m2, intravenous drip, d1. One treatment cycle covered 3 weeks. The effects were evaluated after 2 cycles. Results The effective rate was 33.3% in the trial group, and 26.7% in the control group(P >0.05). The main toxicities were gastrointestinal reactions, bonemarrow toxicity and peripheral neurotoxicity. Conclusion TS-1 capsule combined with oxaliplatin is safe and effective in the treatment of advanced gastric cancer.